VEGFからみたヒト食道扁平上皮癌の悪性度診断と治療への応用

VEGF在人食管鳞癌恶性肿瘤诊治中的应用

• 批准号: 07771012
• 负责人: 石 志紘
• 金额: $ 0.64万
• 依托单位: Keio University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Encouragement of Young Scientists (A)
• 财政年份: 1995
• 资助国家: 日本
• 起止时间: 1995 至 无数据
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-07771012/
• 关键词: VEGF; Northern blot analvsis; mRNA; 食道扁平上皮癌; 微小血管密度; 転移

17種類の扁平上皮癌細胞株(TE1,2,3,4,5,6,8,9,10,11,12,13,14,15,A431,Ca9-22,NA),及び食道扁平上皮癌患者21例,42検体についてNorthern blot法によりVEGFのmRNAの発現を調べた結果以下のことが判った.(1)17種類の扁平上皮癌細胞株全てにおいてVEGFのmRNAの過剰発現を認め,TE13,TE15,A431,NAの4株においては特に過剰な発現を認めた.(2)食道扁平上皮癌組織と正常食道粘膜組織ともにVEGFのmRNA発現を認めた.(3)臨床検体21例中5例において,腫瘍組織におけるVEGFのmRNA発現量は正常食道粘膜に比べ4倍〜26倍の高値を示し,VEGFを過剰発現した5例全てが深達度mp以上の進行癌であり,2例に術後1年以内の肝転移を認めた.(4)同じ病期群における比較において,VEGF過剰発現群は非過剰発現群に比べ転移リンパ節個数が多く,v因子,ly因子陽性率が高い傾向を示した.(5)腫瘍隣接組織中の微小血管密度は54〜164/mm^2であり,VEGFのmRNA過剰発現群と非過剰発現群の腫瘍隣接組織中微小血管密度は各々114±37,78±21/mm^2で過剰発現群の方が有意に高いことが分かった.VEGFは腫瘍血管新生とともに癌細胞の脈管への移行を促進し,食道扁平上皮癌の生物学的悪性度に関連すると考えられ,VEGF-flt系の人為的制御による治療への応用の可能性が示唆された.

17 kinds of squamous cell carcinoma cell lines (TE1,2,3,4,5,6,8,9,10,11,12,13,14,15,A431, Ca9 -22,NA) and 21 patients with esophageal squamous cell carcinoma were detected by Northern blot. (1)17 The expression of VEGF mRNA was detected in all squamous cell carcinoma cell lines, and in 4 squamous cell carcinoma cell lines TE13, TE15,A431,NA. (2)Expression of VEGF mRNA in squamous cell carcinoma of esophagus and normal esophageal mucosa was studied. (3)VEGF mRNA expression in tumor tissue was 4 ~ 26 times higher than that in normal esophageal mucosa in 5 of 21 cases. VEGF mRNA expression was not detected in 5 cases, and liver metastasis was detected in 2 cases within 1 year after operation. (4)The positive rate of VEGF expression in the same disease stage group was higher than that in the non-VEGF expression group. (5)The microvessel density in tumor adjacent tissues ranged from 54 to 164/mm^2.VEGF mRNA overexpression group and non-overexpression group were 114± 37 and 78 ±21/mm^2, respectively.VEGF promoted tumor angiogenesis and migration of cancer cells. VEGF-flt is an artificial control, and the possibility of therapeutic use has been demonstrated.